Current Ebola outbreak possibly intentional, started for vaccination research
The current Ebola outbreak in West Africa might be intentional and part of a larger human anti-Ebola viral therapeutic research program.
In late October 2009, the U.S. Department of Health filed a patent for the Human Ebola Virus Species.
In 2010, Tekmira Pharmaceuticals Corportation signed a $140-million contract with the U.S. Department of Defense, to advance their so-called LNP technology to treat Ebola virus infection.
In January 2014, after successful non-human trials, Tekmira commenced a Phase I clinital trial, a “randomized, single-blind, placebo-controlled study” involving single and multiple ascending doses of TKM-Ebola.
According to the press release, the company had planned four cohorts for a total of 16 subjects in the single dose arm, and three planned cohorts for a total of 12 subjects, meaning the studies are always done in groups of 4.
A month later, Guinea, one of the world’s few non-signatories to the Biological Weapons Convention, experienced corresponding outbreaks in several of its cities: Conakry (four cases), Guéckédougou (four), Macenta (one) and Dabola (one). In the two last locations, the controlled outbreaks appear to not have been fully successful.
As a result of the outbreak, shares of Tekmira (TKMR.O) have skyrocketed, gaining more than 50 percent in the last two weeks.